Canada markets open in 5 hours 26 minutes

Lantheus Holdings, Inc. (LNTH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
23.27+0.12 (+0.52%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close23.15
Open23.14
Bid0.00 x 800
Ask0.00 x 800
Day's Range23.14 - 23.55
52 Week Range10.52 - 28.74
Volume114,554
Avg. Volume392,785
Market Cap1.573B
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-0.41
Earnings DateNov. 03, 2021 - Nov. 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
  • GlobeNewswire

    Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network® (NCCN) Guidelines for Prostate Cancer

    Lantheus’ product, PYLARIFY (piflufolastat F18) injection, is the first and only commercially available and FDA-approved PSMA-targeted PET imaging agent for prostate cancerNORTH BILLERICA, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, an

  • GlobeNewswire

    Lantheus and RefleXion Announce Development and Commercialization Collaboration with the Potential to Improve Future Prostate Cancer Treatment

    NORTH BILLERICA, Mass. and HAYWARD, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) and RefleXion Medical, Inc., today announced a development and commercialization collaboration to evaluate the use of piflufolastat F 18, Lantheus’ prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent, to enable real-time therapeutic guidance of biology-guided radiotherapy1 (BgRT) in prostate cancer using the RefleXion X1™

  • GlobeNewswire

    Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual Meeting

    Highlights Piflufolastat F 18’s Potential to Change Initial Risk Assessment and Intended Patient Management in High-Risk Prostate Cancer Identified Regional Lymph Node and/or Distant Metastases in 26.9% of Patients Prior to Definitive Therapy NORTH BILLERICA, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intellig